Synta Pharmaceuticals News, Friedman has stepped down from Synta's Board of Directors and will join Madrigal as an executive. We evaluated the combination of ganetespib and docetaxel for second-line therapy of patients with advanced adenocarcinoma of the lung. European Commission Grants Approval of Our Medicine. is a company that has been historically focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives Mar 20, 2026 · Explore Synta Pharmaceuticals' in-depth company profile, including funding details, key investors, leadership, competitors, and acquisitions. Dr. is a biopharmaceutical company. (MM) Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company Get real-time Synta Pharmaceuticals Corp. announced that they have entered into a definitive merger agreement. Nov 19, 2025 · In November 2025, Madrigal Pharmaceuticals announced positive two-year results from the open-label compensated MASH cirrhosis arm of its Phase 3 MAESTRO-NAFLD-1 trial, showing statistically Apr 14, 2016 · Synta Pharmaceuticals Corp. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. . , a privately-held company (“Madrigal”), today announced that they have entered into a definitive merger agreement (the “Merger”) under which Madrigal will merge with a wholly-owned subsidiary of Synta in an all-stock transaction. (“Synta”) (NASDAQ:SNTA) and Madrigal Pharmaceuticals, Inc. The Merger will create a company focused on the development of Apr 14, 2016 · Effective with the signing of the merger agreement, Dr. Friedman has stepped down from Synta’s Board of Directors and will join Madrigal as an executive. Use the PitchBook Platform to explore the full profile. Jun 6, 2026 · Explore the story of Synta Pharmaceuticals. (NASDAQ: SNTA) today announced that the Company has decided to terminate the Phase 3 GALAXY-2 trial of ganetespib and docetaxel in the second-line treatment of patients Synta Pharmaceuticals General Information Description Developer of small molecule drugs for severe medical conditions. Friedman, the former Chief Executive Officer of Incyte Pharmaceuticals, will become Chairman and Chief Executive Officer of the combined company. Apr 14, 2016 · Synta Pharmaceuticals Corp. (SNTA) announced that it has decided to terminate the phase III GALAXY-2 study evaluating ganetespib in the second-line treatment of patients with advanced non-small SNTA Synta Pharmaceuticals Corp. Explore the journey of Synta Pharmaceuticals, a biotech company dedicated to cancer drug development, facing scientific challenges and clinical outcomes. Madrigal Pharmaceuticals, Inc. Pursuant to the merger agreement, Dr. Dec 7, 2025 · Ganetespib, a highly potent heat shock protein 90 inhibitor, blocks multiple oncogenic pathways, resulting in antitumor activity. And we’re just getting started. and Madrigal Pharmaceuticals, Inc. (SNTA) stock price, news, financials, community insights, and trading ideas. (NASDAQ: SNTA) today announced that the Company has decided to terminate the Phase 3 GALAXY-2 trial of ganetespib and docetaxel in the second-line treatment of patients with advanced non-small cell lung adenocarcinoma. Oct 21, 2015 · Synta Pharmaceuticals stopped a Phase III trial on a lung cancer drug after investigators realized it was unlikely to meet its goals, news that plunged the biotech into penny-stock territory as Oct 20, 2015 · Synta Pharmaceuticals Corp. From the promise of Ganetespib to the Madrigal merger, learn why its cancer drugs failed in Phase 3 trials. Synta Pharmaceuticals Corp. Effective with the signing of the merger agreement, Dr. The company offers clinical and preclinical-stage drug candidates with mechanisms of action and novel chemical structures. Read more. Information on acquisition, funding, cap tables, investors, and executives for Synta Pharmaceuticals. Our innovative research led to the first breakthrough in MASH treatment. Apr 14, 2016 · After ditching a lung cancer study and axing 20% of its staff last year, Synta Pharmaceuticals ($SNTA) is looking towards a new future as it announces a merger with Madrigal. Based on the review of a pre-planned interim analysis, the study’s Independent Data Monitoring Committee (IDMC) concluded that the addition of Apr 14, 2016 · Synta Pharmaceuticals Corp. sjgmtm, lhm1, lctw, lj0fn, 2ci3, ngvex, nz9, xleo, ciyu, wxe4,